Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases

Oncotarget

Volumn 5, Issue 23, 2014, Pages 12440-12447

  Gatalica, Zoran ^a   Millis, Sherri Z ^a   Vranic, Semir ^b   Bender, Ryan ^a   Basu, Gargi D ^a   Voss, Andreas ^a   Von Hoff, Daniel D ^c  

^a CARIS LIFE SCIENCES   (United States)

^b UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^c Virginia G Piper Charitable Trust   (United States)

Author keywords

Cancer of unknown primary; Molecular profiling; Multiplatform; Mutations; Targeted therapy

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CHILD; COPY NUMBER VARIATION; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; INFANT; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFANT; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; YOUNG ADULT;

EID: 84920031397     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2574     Document Type: Article

References (33)

1. Greco FA. Cancer of unknown primary site: improved patient management with molecular and immunohistochemical diagnosis. Am Soc Clin Oncol Educ Book. 2013; 175-181.
2. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012; 379:1428-1435.
3. Fizazi K, Greco FA, Pavlidis N, et al. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011; 22:vi64-68.
4. Ettinger DS, Handorf CR, Agulnik M, et al. Occult primary, version 3.2014. J Natl Compr Canc Netw. 2014; 12:969-974.
5. Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol. 2009; 36:65-74.
6. Golfinopoulos V, Pentheroudakis G, Salanti G, et al. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev. 2009; 35:570-573.
7. Varadhachary G. New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling. Clin Cancer Res. 2013; 19:4027-4033.
8. Varadhachary GR, Talantov D, Raber MN, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008; 26:4442-4448.
9. Mendelsohn J. Personalizing oncology: perspectives and prospects. J Clin Oncol. 2013; 31:1904-1911.
10. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012; 18:6373-6383.
11. Gatalica Z, Millis S, Chen W, Basu GD, Wen W, Paul L, Bender RP, Von Hoff DD. Integrating molecular profiling into cancer treatment decision, making: experience with over 35,000 cases. J Clin Oncol. 2013;31(suppl; abstr 11001).
12. Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013; 31:217-223.
13. Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med. 2014; 371:757-765.
14. Perkins J, Boland P, Cohen SJ, et al. Successful imatinib therapy for neuroendocrine carcinoma with activating Kit mutation: a case study. J Natl Compr Canc Netw. 2014; 12:847-852.
15. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004; 116:855-867.
16. Murali R, Wiesner T, Rosenblum MK, Bastian BC. GNAQ and GNA11 mutations in melanocytomas of the central nervous system. Acta Neuropathol. 2012; 123:457-459.
17. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502:333-339.
18. Tan DS, Montoya J, Ng QS, et al. Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary. J Clin Oncol. 2013; 31:e237-239.
19. Yamada T, Ohtsubo K, Ishikawa D, et al. Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective. Gan To Kagaku Ryoho. 2012; 39:1291-1294.
20. Tothill RW, Li J, Mileshkin L, et al. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathol. 2013; 231:413-423.
21. Kamposioras K, Pentheroudakis G, Pavlidis N. Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks. Eur J Clin Invest. 2013; 43:491-500.
22. Pentheroudakis G, Kotteas EA, Kotoula V, et al. Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group. Clin Exp Metastasis 2014.
23. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483:100-103.
24. Al-Marrawi MY, Saroya BS, Brennan MC, et al. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther. 2013; 14:703-710.
25. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013; 10:143-153.
26. Owonikoko TK, Khuri FR. Targeting the PI3K/AKT/ mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book 2013.
27. Shimizu T, Tolcher AW, Papadopoulos KP, et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res. 2012; 18: 2316-2325.
28. Ascierto PA, Kalos M, Schaer DA, et al. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res. 2013; 19:1009-1020.
29. Gatalica Z, Snydder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, Overberg P, Rose I, Basu GD, Vranic S, Lynch HT, Von Hoff DD, Hamid O. Programmed cell death (PD-1) and its ligand (PD-L1) expression in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev 2014, in press.
30. Lillie EO, Patay B, Diamant J, et al. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?. Per Med. 2011; 8:161-173.
31. Friboulet L, Olaussen KA, Pignon JP, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013; 368:1101-1110.
32. Millis S, Bryant D, Basu G, Bender R, Vranic S, Gatalica Z, Vogelzang NJ. Theranostic molecular profiling of infiltrating urothelial carcinoma of the bladder. Clinical Genitourinary Cancer 2014 Aug 1, Doi: 10.1016/j.clgc.2014.07.010.
33. NCCNCompendium: http://www.nccn.org/professionals/drug_ compendium/MatrixGenerator/Matrix.aspx?DiseaseID=102.